On this page of StockholderLetter.com we present the latest annual shareholder letter from bluebird bio, Inc. — ticker symbol BLUE. Reading current and past BLUE letters to shareholders can bring important insights into the investment thesis.

 •  9/26/2024 Letter Continued (Full PDF)
 •  4/28/2023 BLUE Stockholder Letter
 •  More "Biotechnology" Category Stockholder Letters
 •  BLUE Benford's Law Stock Score = 76

BLUE Shareholder/Stockholder Letter Transcript:

Fellow shareholders    
At the time of my last letter, bluebird bio was embarking on the penultimate chapter of a decadesjust submitted our Biologics Licensing Application (BLA)
-cel
gene therapy for sickle cell disease. In parallel, we were progressing the simultaneous launches of
ZYNTEGLO    for beta-thalassemia and SKYSONA    for cerebral adrenoleukodystrophy (CALD),
bringing urgently needed treatment options to patients while building the foundation to realize our
largest commercial opportunity yet.
In December, a
, bluebird bio celebrated
LYFGENIA      a potentially
gene therapy for sickle cell disease. This was a watershed
moment for the sickle cell disease community, for our company, and for our entire industry. Today,
a
transformational new options that can alter the course of their disease.
ancement of this magnitude. With your support, we made history   and we are
continuing to work to make this long-awaited option a reality for patients in the commercial setting.
Timely and equitable access to new therapies
That principle is the cornerstone of our commercial strategy, which was
experience prior to LYFGENIA   s

e.
Our network of treatment centers was unparalleled at launch, with 27 centers
patient referrals on    Day 1      and it remains unmatched today. Less than nine months after
more than 70 centers currently
onboarding process across our network   
, as well as their
trust in bluebird as an experienced partner. As I write this letter, nearly 100 patient
are scheduled to initiate a bluebird gene therapy across more than 30 centers, with capacity for
cross the full network.
M
announced that 1
a month, and w
payer
bluebird
. Th
doubled within
-based agreement with a Medicaid
were
of 2024.
breadth
, and
are prepared to support access.
our clinical experience and followup data. At the American Society of Hematology Annual Meeting in December, bluebird presented
patients treated, and longest followtrust and transparency.
   which is critical for
The demand for

and we
infrastructure, relationships, and realYet, as we know from our
experience with ZYNTEGLO and SKYSONA, translating early commercial momentum
takes time.
As I write you today, bluebird sits in a class of its own. We are the only independent company with 3
and we are making a
most
diseases. Beyond our near-term, billion-dollar commercial opportunities, we occupy a unique
through regulatory
, to scaling commercial manufacturing. We plan to continue to take steps to strengthen our
balance sheet and extend our cash runway so we can cross the bridge to sustainability and realize
both our immediate commercial opportunities and long-term growth potential.
   and we are continually reminded of
by the patients and families
We remain committed to
realizing the commercial promise of gene therapy and forging
day, we are persisting for patients   those who
put their trust in us today and
can transform tomorrow. Thank you for being on this journey alongside us.
Onward,
Andrew




 9/26/2024 Letter Continued (Full PDF)